|
Attention deficit hyperactivity disorder
|
0.100 |
Biomarker
|
disease |
BEFREE |
A subgroup of 18 patients with ADHD and 18 healthy controls underwent positron emission tomography (PET) with the radioligand (S,S)-[<sup>18</sup>F]FMeNER-D<sub>2</sub> to quantify the NET in several brain areas in vivo.
|
31383926 |
2019 |
|
Attention deficit hyperactivity disorder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overall our findings demonstrate the pathophysiological involvement of NET availability in adult ADHD.
|
31732713 |
2019 |
|
Attention deficit hyperactivity disorder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The present study aimed to examine whether the SLC6A2 rs36011 (T)/rs1566652 (G) haplotype affected the intrinsic brain activity in children with ADHD and whether these gene-brain modulations were associated with visual memory and attention in this population.
|
31595036 |
2019 |
|
Attention deficit hyperactivity disorder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Six single nucleotide polymorphisms (rs28386840, rs2242446, rs3785143, rs3785157, rs5569, rs7194256 SNP) were studied across the NET gene in 163 ADHD children (age: 9.3±2.6; 86.5% male) using ADHD-RS hyperactivity-impulsivity and inattention scales.
|
29374517 |
2018 |
|
Attention deficit hyperactivity disorder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Based on previous reports of lower NE levels in ADHD children and the inverted-U shape effect of NE on cognitive functions, we propose that rs28386840 (-3081) T-allele, which is associated with lower NET expression (and potentially higher synaptic NE level) would support attention processes among ADHD patients (similarly as atomoxetine increases NE levels), whereas it would hinder cortical functions in healthy children.
|
30692908 |
2018 |
|
Attention deficit hyperactivity disorder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Therefore, we conducted an imaging genetics study to examine possible effects of single nucleotide polymorphisms (SNPs) within the NET gene on NET nondisplaceable binding potential (BPND ) in patients with ADHD and healthy controls (HCs).
|
26678348 |
2016 |
|
Attention deficit hyperactivity disorder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Given the modulation of the norepinephrine transporter (NET) on NE levels in the brain and the link between NE and attention impairment of attention-deficit hyperactivity disorder, it was possible that the NET gene underpinned individual differences in attention processes in healthy populations.
|
27541794 |
2016 |
|
Attention deficit hyperactivity disorder
|
0.100 |
Biomarker
|
disease |
BEFREE |
After correcting for multiple testing, we found several significant associations between the polymorphisms and ADHD (p value corrected ≤0.05): (1) SLC6A4 and LPHN3 were associated in the total population; (2) SLC6A2, SLC6A3, SLC6A4 and LPHN3 were associated in the combined subtype; and (3) LPHN3 was associated in the male sample.
|
26746237 |
2016 |
|
Attention deficit hyperactivity disorder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our novel finding of the haplotype rs36011 (T)/rs1566652 (G) as a novel genetic marker involved in both ADHD disease susceptibility and visual memory suggests that allelic variations in SLC6A2 could provide insight into the pathways leading from genotype to phenotype of ADHD.
|
25554436 |
2015 |
|
Attention deficit hyperactivity disorder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Association of SNAP-25, SLC6A2, and LPHN3 with OROS methylphenidate treatment response in attention-deficit/hyperactivity disorder.
|
25229170 |
2015 |
|
Attention deficit hyperactivity disorder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Atomoxetine, a selective inhibitor of the norepinephrine transporter, exerts its therapeutic effect for attention-deficit hyperactivity disorder (ADHD) by increasing the concentration of synaptic norepinephrine.
|
23266789 |
2013 |
|
Attention deficit hyperactivity disorder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Additive regression analyses controlling for ADHD symptom severity, age, sex, IQ, and final dose of MPH examined the association between response time variability on the comprehensive attention test measures and allelic variations in single-nucleotide polymorphisms of the ADRA2A and SLC6A2 before and after MPH treatment.Increasing possession of an A allele at the G1287A polymorphism of SLC6A2 was significantly related to heightened response time variability at baseline in the sustained (P = 2.0 × 10) and auditory selective attention (P = 1.0 × 10) tasks.
|
23609393 |
2013 |
|
Attention deficit hyperactivity disorder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In contrast, haplotype analyses demonstrated a significant association between ADHD and a SLC6A2 haplotype comprising the markers rs36009, rs1800887, rs8049681, rs2242447 and rs9930182 (χ(2) = 9.39, p-corrected = 0.019, OR = 1.51).
|
23052569 |
2013 |
|
Attention deficit hyperactivity disorder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Children with ADHD having the T/T genotype of SLC6A2 showed a 12.5% increase in HR compared to baseline, whereas children with the A/T or A/A genotype showed a 3.5% and 2.5% increase after OROS-MPH treatment, respectively.
|
21628343 |
2012 |
|
Attention deficit hyperactivity disorder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We conducted a family-based study, with stratification based on sex and subtype, to test the association between 30 tag single-nucleotide polymorphisms (SNPs) within the gene encoding NET (SLC6A2) and ADHD.
|
22297068 |
2012 |
|
Attention deficit hyperactivity disorder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our results provide evidence for the possible role of the G1287A and A-3081T genotypes of SLC6A2 in methylphenidate-induced improvement in attentional performance and support the noradrenergic hypothesis for the pathophysiology of ADHD.
|
22591463 |
2012 |
|
Attention deficit hyperactivity disorder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study intended to examine the differences in methylphenidate (MPH) treatment response and pre- and post-treatment cerebral perfusion associated with the G1287A and -3081(A/T) polymorphisms of the norepinephrine transporter (NET) gene in ADHD children.
|
22405810 |
2012 |
|
Attention deficit hyperactivity disorder
|
0.100 |
Biomarker
|
disease |
BEFREE |
We aimed to investigate the independent and interaction effects of dopamine transporter gene (DAT1), dopamine D4 receptor gene (DRD4), alpha-2A adrenergic receptor gene (ADRA2A), and norepinephrine transporter gene (NET1), with regard to treatment response to methylphenidate (MPH) in attention-deficit/hyperactivity disorder (ADHD).
|
23083021 |
2012 |
|
Attention deficit hyperactivity disorder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our study found a significant association between the G1287A genotype of the NET gene and the MPH response in Korean children with ADHD.
|
21127421 |
2011 |
|
Attention deficit hyperactivity disorder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Lack of association between response of OROS-methylphenidate and norepinephrine transporter (SLC6A2) polymorphism in Korean ADHD.
|
20863575 |
2011 |
|
Attention deficit hyperactivity disorder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The 1287 G/A polymorphism of the norepinephrine transporter gene (NET) is involved in commission errors in Korean children with attention deficit hyperactivity disorder.
|
21569456 |
2011 |
|
Attention deficit hyperactivity disorder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our findings provide evidence for the involvement of the -3081(A/T) polymorphism of SLC6A2 in the modulation of the effectiveness of MPH treatment in ADHD.
|
20929549 |
2010 |
|
Attention deficit hyperactivity disorder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Association studies of -3081(A/T) polymorphism of norepinephrine transporter gene with attention deficit/hyperactivity disorder in Korean population.
|
19685476 |
2010 |
|
Attention deficit hyperactivity disorder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Clinical efficacy of atomoxetine treatment in ADHD shows potential dependence upon a series of genetic polymorphisms of its mechanistic target, the norepinephrine transporter.
|
19387424 |
2009 |
|
Attention deficit hyperactivity disorder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Identification of polymorphic sites within NET, specifically those that produce functional consequences, is one critical step in elucidating the genetic variation contributing to the heritable component of diseases such as ADHD.
|
19698724 |
2009 |